1itigation. Ms. Blais has handled numerous patent infringement lawsuits in federal courts nationwide. She has advised clients and participated in all phases of patent litigation, from initial counseling up

a range of fields including IT consulting, operations and logistics management, and served as a live-in assistant for mentally handicapped adults in L'Arche communities in both Canada and Germany. Dr. Buckley received his B.A. in 1991 in Mathematics from the University of Pennsylvania, his M.A. in 2001 and his Ph.D. in 2004 in Applied Economics from the Wharton School of Business, University of Pennsylvania.

Kenneth J. Dow, JD

Kenneth J. Dow is Assistant Patent Counsel at Johnson & Johnson and Vice President, Patent Law at Centocor, Inc., a biotechnology company which is a wholly owned subsidiary of Johnson & Johnson. At Centocor, Mr. Dow is a member of the research management board and is responsible for overseeing all patent matters, including patent preparation and prosecution, infringement and validity opinions, and licensing matters. Prior to joining Centocor, Mr. Dow represented the pharmaceutical group within Johnson & Johnson, where he did work for Ortho-McNeil Pharmaceutical, Inc., Janssen Pharmaceuticals, and the R.W. Johnson Pharmaceutical Research Institute. Prior to joining Johnson & Johnson, Mr. Dow was employed as a patent attorney for American Cyanamid Company where he represented the Lederle Pharmaceuticals division, including the generic drug business of Lederle. He was also an associate attorney at the law firm of Morgan & Finnegan. Mr. Dow received his B.S. in Pharmacy from the State University of New York at Buffalo and his J.D. from St. John's University.

Suzanne Drennon, JD

Suzanne Drennon is Counsel for Intellectual Property in the Office of Policy and Coordination with the Bureau of Competition of the Federal Trade Commission and focuses on antitrust and intellectual property policy and enforcement. Suzanne speaks on Hatch-Waxman and follow-on biologics issues and publishes articles analyzing antitrust issues. Prior to joining the FTC, Suzanne was an antitrust and intellectual property litigator in Los Angeles. She received her A.B. in

both St. Anthony Hospital and Cook County Hospital in Chicago, Illinois. Mr. Golding earned his Bachelor of Science degree in pharmacy from the University of Illinois at Chicago, College of Pharmacy.

Ken Goldman, MS, JD

Ken Goldman is a Director, IP Strategy for Novartis Corporation. Ken has more than 20 years of IP experience, largely in the biotech area. Ken began his patent career at the Biotech specialty firm of Ciotti, Murashage, Irell and Manella, moving subsequently to Morrison & Foerster. He has 15 years of in-house patent counsel experience at biotechnology companies, including seven years at Chiron Corporation, and eight years as chief patent counsel at Cell Genesys, Inc. and Dynavax Technologies Corporation. Ken graduated from Harvard University, *summa cum laude*, with a dual-degree in Chemistry and Physics in 1981. He received a MS in Chemistry in 1985 from the University of California, Berkeley, and a JD from Berkeley's Boalt Hall School of Law in 1988.

Mark A. Goshko, MS

Mitsubishi, each resulting in multimillion-dollar national consumer settlements. Among her most notable antitrust cases were New York v. May Department Stores, a successful anti-merger

graduate of Williams College, and obtained her Juris Doctor from Georgetown University Law Center.

Esther M. Kepplinger

Esther Kepplinger is Wilson Sonsini Goodrich & Rosati's director of patent operations. She serves as a liaison with the PTO enhancing the firm's practice before the PTO and she provides client strategic patent counseling. Prior to joining the firm in 2005, Ms. Kepplinger served as the Deputy Commissioner for Patent Operations for five years at the USPTO. She holds a BS in biology from Indiana University of Pennsylvania and completed 2 years of graduate studies in biochemistry.

Jeffrey P. Kushan, JD

Jeffrey P. Kushan is a partner with Sidley Austin, LLP, in Washington, D.C., and heads the Firm's D.C. patent group. He specializes in Hatch-Waxman patent litigation, patent appeals, and complex patent administrative proceedings. He also represents clients on domestic and international patent policy matters. Before entering private practice, Mr. Kushan gained extensive experience in patent policy through positions he held in the Patent and Trademark Office and the Office of the U.S. Trade Representative. Mr. Kushan began his career as a patent examiner in 1987, where he was responsible for assessing the patentability of biotechnology therapeutics and diagnostic agents. Mr. Kushan is a graduate of the College of William and Mary, and obtained his JD from the George Washington University Law School and a MA in Chemistry from the University of North Carolina at Chapel Hill.

John A. Lane, MBA

John Lane is Vice President, Biologics, Global Pharmaceuticals for Hospira Inc., the world leader in generic injectable pharmaceuticals. During his tenure at Hospira, Lane has played a key role in establishing the company's biogenerics business. Among other initiatives, he led Hospira's efforts to establish an alliance with STADA for an erythropoietin (EPO) and to acquire the Australian biotech firm BresaGen. Prior to assuming his current position in early 2007, Lane was director, Global Business Development, for Hospira, a role he held since the company's spin-off from Abbott Laboratories in 2004. Lane held a variety of roles during his sixteen preceding years with Abbott. He spent eleven years within the company's finance organization. During the balance of his Abbott career, Lane worked in business development, including two years supporting the hospital products business. Lane earned a Bachelor's degree in finance from the University of Iowa, and a MBA from Northwestern University. He currently serves on the Board of Directors for Illinois Biotechnology Industry Organization

Bruce A. Leicher, JD

Mr. Leicher is Senior Vice President and General Counsel at Momenta Pharmaceuticals Inc., an innovative biotechnology company engaged in development of complex generic products and biogenerics, with 18 years legal experience in the biotechnology industry. Before joining Momenta, he served in senior legal positions at Altus Pharmaceuticals Inc., Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc. and Wyeth. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow, and was an attorney at Hale & Dorr and Butler & Binion after receiving his J.D. from Georgetown University Law Center and his B.A. from the University of Rochester.

David Manspeizer, JD

David A. Manspeizer is Vice President Intellectual Property and Associate General Counsel at Wyeth, one of the world's largest research-driven pharmaceutical companies. The Company discovers, develops, manufactures, and market

received his J.D. from the University of Virginia Law School (1974) and his BA from Yale University (1970).

Rochelle Seide, JD

Dr. Rochelle Seide is currently Senior Counsel with Schwegman, Lundberg & Woessner. Her practice encompasses all facets of patent law, including litigation, written opinions, patent strategies and transactional matters, particularly in the life sciences. She has obtained patents in the areas of biotechnology, chemistry, and pharmaceuticals for a variety of clients. Rochelle also counsels clients on legal issues relating to biotechnology, chemical and pharmaceutical patents, including patent enforcement, validity and infringement, licensing and business development. She has broad experience in transactional matters for biotechnology and pharmaceutical clients. Rochelle also represents clients in patent litigations before the federal courts, as well as in patent interferences in the US Patent and Trademark Office, in biotechnology, pharmaceutical and medical device technologies. While attending law school, she was an instructor/assistant professor of medical genetics and microbiology at the Northeastern Ohio Universities College of Medicine and worked as a genetics counselor at the Akron Children's Medical Center.

Rochelle was a member of the National Academy of Sciences' Committee on Intellectual Property in Genomic and Protein Research and Innovation. She is a member of the Association of the Bar of the City of New York; the American Bar Association; the Biotechnology Industrial Organization Intellectual Property Counsel's Committee and the American Chemical Society. Rochelle is an active member of the American Intellectual Property Law Association (having served as chair of its Biotechnology Committee) and the New York Intellectual Property Law Association (where she is a past chair of the Public Information and Education Committee and the Legislative Oversight and Amicus Briefs Committee). She is a member of the advisory council to the University of Akron School of Law's Center for Intellectual Property Law. Rochelle is also a member of the board of directors of the National Inventors Hall of Fame and the Biojudiciary Project.

Recognized as an expert in her field, Rochelle is listed in the Chambers USA Guide,

Mateja Urlep RPh

Mateja Urlep is a pharmacist with 17 years experience in the field and has held management positions in several areas, including development, production, marketing and sales, and academia. As the head of Global Marketing and Medical team at Sandoz (Novartis), she is responsible for establishing and guiding all marketing activities of biosimilar biopharmaceutical products. She also coordinates specific country operations for marketing, launch plans, and commercialization strategies for the company's overall biosimilar biopharmaceuticals portfolio. As the leader, she ensures that the pipeline and portfolio are aligned with market strategies and requirements. Prior to taking on this position, Mateja was the Head of the Centre of Excellence in Mengeš, where she led biopharmaceutical development and production from 2001 to 2007. During this time, she served for two years as Sandoz's Head Biopharmaceutical Franchise CEE, responsible for regional activities of the business in development, production, marketing, and sales.

Michael Wroblewski, JD, MPA

Michael Wroblewski returned to the FTC in June 2008 as an attorney in the FTC's Bureau of Competition. From 1998-2006, Mr. Wroblewski served in several capacities at the FTC, including Assistant General Counsel for Policy Studies in the Office of the General Counsel, and as an attorney advisor to Commissioner Leary. During this time, he directed many of the Commission's efforts to study competition issues in the pharmaceutical and electric power industries. He oversaw the Commission's efforts to examine whether a conflict of interest exists when a pharmacy benefit manager (PBM) owns a mail-order pharmacy and to examine the competition issues raised by the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act, which govern the approval of generic drug products. He is the primary author of the 2005 FTC Report *Pharmacy Benefit Managers: Ownership of Mail-Order Pharmacies*, and of the 2002 FTC study *Generic Drug Entry Prior to Patent Expiration*. He is the primary author of two reports (2000 and 2001) that examined competition and consumer protection issues in the electric power industry. In 2007 and 2008, Mr. Wroblewski workd comp